Press release
Colorectal Cancer Pipeline Assessment | In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Colorectal Cancer Pipeline
"Colorectal Cancer Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Colorectal Cancer Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Download the sample pages:
https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Colorectal Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights about companies that are developing therapies in the Colorectal Cancer Market.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer treatment.
• Colorectal Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Colorectal Cancer Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Colorectal Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF:
https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Colorectal Cancer Therapeutics Analysis
There are approx. 150+ key companies which are developing therapies for Colorectal Cancer. Currently, Mirati Therapeutics has its Colorectal Cancer drug candidates in the most advanced stage of clinical development.
Colorectal Cancer Therapies covered in the report include:
Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, MacroGenics, Amgen, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Dainippon Pharma, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Merck Sharp & Dohme Corp., AstraZeneca, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Pregen ShenZhen Biotechnology, Puma Biotechnology, G1 Therapeutics, Mologen AG, Sumitomo Dainippon Pharma, Celyad Oncology, Nitto BioPharma, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, AbGenomics B.V, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc. and Others
Colorectal Cancer Therapies covered in the report include:
• Patritumab Deruxtecan (Daiichi Sankyo Company)
• Adagrasib (Mirati Therapeutics)
• Etrumadenant (Arcus Bioscience)
• AL2846 (Advenchen Laboratories)
• Onvansertib (Cardiff Oncology)
And many more
Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Colorectal Cancer Current Treatment Patterns
4. Colorectal Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Colorectal Cancer Late Stage Products (Phase-III)
7. Colorectal Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Colorectal Cancer Discontinued Products
13. Colorectal Cancer Product Profiles
14. Colorectal Cancer Key Companies
15. Colorectal Cancer Key Products
16. Dormant and Discontinued Products
17. Colorectal Cancer Unmet Needs
18. Colorectal Cancer Future Perspectives
19. Colorectal Cancer Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at: https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Colorectal Cancer Pipeline Assessment | In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies here
News-ID: 2706553 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Colorectal
Metastatic Colorectal Cancer Therapeutics Market - Innovation in Motion: Elevate …
Newark, New Castle, USA: The "Metastatic Colorectal Cancer Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Metastatic Colorectal Cancer Therapeutics Market: https://www.growthplusreports.com/report/metastatic-colorectal-cancer-therapeutics-market/8685
This latest report researches the…
Potential Opportunities of Colorectal Cancer Therapeutics Market
The global colorectal cancer therapeutics market size is projected to reach USD 16.58 billion by 2026, owing to the rise in the prevalence of colorectal cancer worldwide. A report by Fortune Business Insights(TM) titled, "Colorectal Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Others), By Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and…
Colorectal Cancer Pipeline Therapeutic Review H1 2017
Colorectal Cancer Pipeline Review H1 2017 provides an overview of the Colorectal Cancer (Oncology) pipeline landscape. Colorectal cancer is cancer that starts in the large intestine (Colorectal). There is no single cause of colorectal cancer. Nearly all colorectal cancers begin as noncancerous (benign) polyps, which slowly develop into cancer.
For More on Colorectal Cancer Pipeline Review H1 2017 Report Inquire @
https://goo.gl/1HQ4Fn .
Report Description:
Pharmaceutical guide Colorectal Cancer - Pipeline Review H1…
US Colorectal Cancer Drug Pipeline Analysis
Among all the regions affected with colorectal cancer, the US would continue to account for a giant’s share owing to its huge population base. With regards to rates of increase, it is most likely that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions of the disease. According to estimates, approximately 55,000 people die…
Colorectal Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Colorectal Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in…
Colorectal Cancer Treatment Market- Global Outlook 2024
Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of the large intestine, which is the lower part of the body’s digestive system. The colon absorbs water and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which…
